XML 45 R34.htm IDEA: XBRL DOCUMENT v3.25.2

Segment Information (Tables)

6 Months Ended

Jun. 30, 2025

Segment Reporting [Abstract]

Schedule of Net Sales and Operating Earnings by Segment

The following segment information has been prepared in accordance with the internal accounting policies of Abbott, as described above, and is not presented in accordance with generally accepted accounting principles applied to the consolidated financial statements.

						Net Sales to External Customers												Cost of Products Sold												Research and Development												Selling, General and Administrative												Operating Earnings
						Three Months Ended June 30,												Three Months Ended June 30,												Three Months Ended June 30,												Three Months Ended June 30,												Three Months Ended June 30,
(in millions)						2025						2024						2025						2024						2025						2024						2025						2024						2025						2024
Established Pharmaceuticals						$	1,383					$	1,294					$	(631)					$	(591)					$	(43)					$	(44)					$	(363)					$	(344)					$	346					$	315
Nutritionals						2,212						2,150						(1,155)						(1,148)						(54)						(53)						(585)						(576)						418						373
Diagnostics						2,173						2,195						(1,224)						(1,203)						(154)						(162)						(423)						(400)						372						430
Medical Devices						5,369						4,734						(1,758)						(1,627)						(430)						(379)						(1,385)						(1,221)						1,796						1,507
Total						$	11,137					$	10,373					$	(4,768)					$	(4,569)					$	(681)					$	(638)					$	(2,756)					$	(2,541)					$	2,932					$	2,625
Other						5						4
Net sales						$	11,142					$	10,377
Corporate functions and plan benefit costs																																																						(65)						(80)
Net interest expense																																																						(50)						(58)
Share-based compensation (a)																																																						(142)						(141)
Amortization of Intangible assets																																																						(420)						(471)
Other, net (b)																																																						(105)						(268)
Earnings before Taxes																																																						$	2,150					$	1,607

						Net Sales to External Customers												Cost of Products Sold												Research and Development												Selling, General and Administrative												Operating Earnings
						Six Months Ended  June 30,												Six Months Ended  June 30,												Six Months Ended  June 30,												Six Months Ended  June 30,												Six Months Ended  June 30,
(in millions)						2025						2024						2025						2024						2025						2024						2025						2024						2025						2024
Established Pharmaceuticals						$	2,643					$	2,520					$	(1,200)					$	(1,175)					$	(85)					$	(85)					$	(714)					$	(678)					$	644					$	582
Nutritionals						4,358						4,218						(2,279)						(2,236)						(106)						(105)						(1,161)						(1,127)						812						750
Diagnostics						4,227						4,409						(2,376)						(2,391)						(305)						(317)						(815)						(797)						731						904
Medical Devices						10,264						9,187						(3,356)						(3,174)						(831)						(747)						(2,672)						(2,399)						3,405						2,867
Total						$	21,492					$	20,334					$	(9,211)					$	(8,976)					$	(1,327)					$	(1,254)					$	(5,362)					$	(5,001)					$	5,592					$	5,103
Other						8						7
Net sales						$	21,500					$	20,341
Corporate functions and plan benefit costs																																																						(93)						(146)
Net interest expense																																																						(99)						(119)
Share-based compensation (a)																																																						(431)						(445)
Amortization of Intangible assets																																																						(840)						(943)
Other, net (b)																																																						(201)						(407)
Earnings before Taxes																																																						$	3,928					$	3,043

______________________________________

(a)			Approximately 45 percent of the annual net cost of share-based awards will typically be recognized in the first quarter due to the timing of the granting of share-based awards.
(b)			Other, net for the three and six months ended June 30, 2025 and 2024 includes charges related to restructurings, fair value adjustments to contingent consideration and integration costs related to business combinations. Other, net for the six months ended June 30, 2025 and 2024 also includes impairment charges related to various investments. Other, net for the three and six months ended June 30, 2024 also includes charges related to the impairment of IPR&D assets, as well as a loss on the divestiture of a non-core business.

Schedule of Depreciation, Additions to Property and Equipment, and Total Assets by Segment

						Depreciation												Additions to Property and Equipment
						Three Months Ended June 30,												Three Months Ended June 30,
(in millions)						2025						2024						2025						2024
Established Pharmaceuticals						$	25					$	24					$	39					$	37
Nutritionals						44						39						81						103
Diagnostics						135						129						166						169
Medical Devices						94						87						145						158
Total Reportable Segments						298						279						431						467
Other						59						55						62						68
Total						$	357					$	334					$	493					$	535

						Depreciation												Additions to Property and Equipment
						Six Months Ended June 30,												Six Months Ended June 30,
(in millions)						2025						2024						2025						2024
Established Pharmaceuticals						$	48					$	48					$	72					$	66
Nutritionals						86						78						160						176
Diagnostics						261						258						301						292
Medical Devices						182						174						301						293
Total Reportable Segments						577						558						834						827
Other						116						109						122						117
Total						$	693					$	667					$	956					$	944

Schedule of Reconciliation of Segment Assets to Total Assets

						Total Assets
						As of June 30,						As of December 31,
(in millions)						2025						2024
Established Pharmaceuticals						$	3,732					$	3,087
Nutritionals						4,910						4,404
Diagnostics						8,177						7,678
Medical Devices						10,555						9,472
Total Reportable Segment Assets						$	27,374					$	24,641
Cash and investments						8,240						8,853
Goodwill and intangible assets						29,872						29,755
All other (c)						18,513						18,165
Total Assets						$	83,999					$	81,414

(c) As of June 30, 2025 and December 31, 2024, all other includes the long-term assets associated with the defined benefit plans and certain deferred tax assets.

X

- Definition

Tabular disclosure of all significant reconciling items in the reconciliation of total depreciation and additions to property, plant and equipment from reportable segments to the entity's consolidated amounts and segment assets

+ References

No definition available.

+ Details

Name:	abt_ReconciliationOfDepreciationAdditionsToPropertyPlantAndEquipmentFromSegmentToConsolidatedAndAssetsBySegmentTableTextBlock
Namespace Prefix:	abt_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of all significant reconciling items in the reconciliation of total assets from reportable segments to the entity's consolidated assets.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-31

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-30

+ Details

Name:	us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 25
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-25

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-30

+ Details

Name:	us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- References

No definition available.

+ Details

Name:	us-gaap_SegmentReportingAbstract
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration